APO RESEARCH · REPORT
Epirubicin Hydrochloride API
Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin.
Product & engineering
Understand the product.
Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin. Its chemical name is (8S-cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride, with the molecular formula C27H29NO11·HCl and a molecular weight of 579.98. The active moiety is a red-orange hygroscopic powder that exerts its antitumor effects through multiple mechanisms, including intercalation of its planar rings between DNA base pairs to inhibit nucleic acid and protein synthesis, stimulation of topoisomerase II-mediated DNA strand breaks, and generation of cytotoxic free radicals via redox cycling.
The API is manufactured via a semi-synthetic process that begins with microbial fermentation of appropriate Streptomyces strains to produce daunorubicin or 4'-epi-daunorubicin precursors, followed by chemical modification to invert the stereochemistry at the 4' position of the daunosamine sugar moiety. Key steps include formation of bromo-ketal intermediates, hydrolysis, oxidation, and purification through ion-exchange resins in chloride form, followed by adsorption chromatography, concentration, and final crystallization of the hydrochloride salt under controlled pH and solvent conditions to achieve pharmacopeial purity and stability.
Epirubicin hydrochloride is indicated as a component of adjuvant therapy in patients with primary breast cancer and axillary lymph node involvement following surgical resection, where it is administered intravenously in combination regimens to reduce recurrence risk. It is also used in the treatment of advanced or metastatic breast cancer and other malignancies including gastric carcinoma, ovarian carcinoma, lung carcinoma, soft-tissue sarcomas, malignant lymphomas, and certain leukemias, with dosing individualized according to body surface area and hepatic function to balance efficacy against risks of myelosuppression and cumulative cardiotoxicity.
The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.
What turns activity into demand
Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.
The commercial boundary
For Epirubicin Hydrochloride API, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.
Which conditions determine usable epirubicin hydrochloride api performance?
Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.
Selected research
Market Structure
Global Epirubicin Hydrochloride API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin. Its chemical name is (8S-cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride, with the molecular formula C27H29NO11·HCl and a molecular weight of 579.98. The active moiety is a red-orange hygroscopic powder that exerts its antitumor effects through multiple mechanisms, including intercalation of its planar rings between DNA base pairs to inhibit nucleic acid and protein synthesis, stimulation of topoisomerase II-mediated DNA strand breaks, and generation of cytotoxic free radicals via redox cycling.
The API is manufactured via a semi-synthetic process that begins with microbial fermentation of appropriate Streptomyces strains to produce daunorubicin or 4'-epi-daunorubicin precursors, followed by chemical modification to invert the stereochemistry at the 4' position of the daunosamine sugar moiety. Key steps include formation of bromo-ketal intermediates, hydrolysis, oxidation, and purification through ion-exchange resins in chloride form, followed by adsorption chromatography, concentration, and final crystallization of the hydrochloride salt under controlled pH and solvent conditions to achieve pharmacopeial purity and stability.
Epirubicin hydrochloride is indicated as a component of adjuvant therapy in patients with primary breast cancer and axillary lymph node involvement following surgical resection, where it is administered intravenously in combination regimens to reduce recurrence risk. It is also used in the treatment of advanced or metastatic breast cancer and other malignancies including gastric carcinoma, ovarian carcinoma, lung carcinoma, soft-tissue sarcomas, malignant lymphomas, and certain leukemias, with dosing individualized according to body surface area and hepatic function to balance efficacy against risks of myelosuppression and cumulative cardiotoxicity.
Read the full market overview
The global Epirubicin Hydrochloride API market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Asia Pacific market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Epirubicin Hydrochloride API include Synbias-Gemini, TAPI, MicroBiopharm Japan, Olon S.p.A., Sterling Biotech, Lunan Pharmaceutical, Zhejiang Hisun and DZD (Heze) Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Epirubicin Hydrochloride API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Epirubicin Hydrochloride API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Epirubicin Hydrochloride API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Epirubicin Hydrochloride API market size, projected growth trends, production technologies, key applications, and end-use industries.
Epirubicin Hydrochloride API Segment by Company
Synbias-Gemini
TAPI
MicroBiopharm Japan
Olon S.p.A.
Sterling Biotech
Lunan Pharmaceutical
Zhejiang Hisun
DZD (Heze) Pharmaceutical
Epirubicin Hydrochloride API Segment by Type
USP Grade
EP Grade
CP Grade
JP Grade
BP Grade
Others
Epirubicin Hydrochloride API Segment by Application
Injection
Freeze-dried Powder Injection
Epirubicin Hydrochloride API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epirubicin Hydrochloride API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epirubicin Hydrochloride API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epirubicin Hydrochloride API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Epirubicin Hydrochloride API market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Epirubicin Hydrochloride API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Epirubicin Hydrochloride API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Epirubicin Hydrochloride API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- USP Grade
- EP Grade
- CP Grade
- JP Grade
- BP Grade
- Others
Applications
- Injection
- Freeze-dried Powder Injection
Companies covered
- Synbias-Gemini
- TAPI
- MicroBiopharm Japan
- Olon S.p.A.
- Sterling Biotech
- Lunan Pharmaceutical
- Zhejiang Hisun
- DZD (Heze) Pharmaceutical
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Epirubicin Hydrochloride API Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Epirubicin Hydrochloride API Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Epirubicin Hydrochloride API Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Epirubicin Hydrochloride API Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Epirubicin Hydrochloride API Market Dynamics
- 2.1 Epirubicin Hydrochloride API Industry Trends
- 2.2 Epirubicin Hydrochloride API Industry Drivers
- 2.3 Epirubicin Hydrochloride API Industry Opportunities and Challenges
- 2.4 Epirubicin Hydrochloride API Industry Restraints
3 Epirubicin Hydrochloride API Market by Manufacturers
- 3.1 Global Epirubicin Hydrochloride API Revenue by Manufacturers (2021-2026)
- 3.2 Global Epirubicin Hydrochloride API Sales by Manufacturers (2021-2026)
- 3.3 Global Epirubicin Hydrochloride API Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Epirubicin Hydrochloride API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Epirubicin Hydrochloride API Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Epirubicin Hydrochloride API Manufacturers, Product Type & Application
- 3.7 Global Epirubicin Hydrochloride API Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Epirubicin Hydrochloride API Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Epirubicin Hydrochloride API Players Market Share by Revenue in 2025
- 3.8.3 2025 Epirubicin Hydrochloride API Tier 1, Tier 2, and Tier 3
4 Epirubicin Hydrochloride API Market by Type
- 4.1 Epirubicin Hydrochloride API Type Introduction
- 4.1.1 USP Grade
- 4.1.2 EP Grade
- 4.1.3 CP Grade
- 4.1.4 JP Grade
- 4.1.5 BP Grade
- 4.1.6 Others
- 4.2 Global Epirubicin Hydrochloride API Sales by Type
- 4.2.1 Global Epirubicin Hydrochloride API Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Epirubicin Hydrochloride API Sales by Type (2021-2032)
- 4.2.3 Global Epirubicin Hydrochloride API Sales Market Share by Type (2021-2032)
- 4.3 Global Epirubicin Hydrochloride API Revenue by Type
- 4.3.1 Global Epirubicin Hydrochloride API Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Epirubicin Hydrochloride API Revenue by Type (2021-2032)
- 4.3.3 Global Epirubicin Hydrochloride API Revenue Market Share by Type (2021-2032)
5 Epirubicin Hydrochloride API Market by Application
- 5.1 Epirubicin Hydrochloride API Application Introduction
- 5.1.1 Injection
- 5.1.2 Freeze-dried Powder Injection
- 5.2 Global Epirubicin Hydrochloride API Sales by Application
- 5.2.1 Global Epirubicin Hydrochloride API Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Epirubicin Hydrochloride API Sales by Application (2021-2032)
- 5.2.3 Global Epirubicin Hydrochloride API Sales Market Share by Application (2021-2032)
- 5.3 Global Epirubicin Hydrochloride API Revenue by Application
- 5.3.1 Global Epirubicin Hydrochloride API Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Epirubicin Hydrochloride API Revenue by Application (2021-2032)
- 5.3.3 Global Epirubicin Hydrochloride API Revenue Market Share by Application (2021-2032)
6 Global Epirubicin Hydrochloride API Sales by Region
- 6.1 Global Epirubicin Hydrochloride API Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Epirubicin Hydrochloride API Sales by Region (2021-2032)
- 6.2.1 Global Epirubicin Hydrochloride API Sales by Region (2021-2026)
- 6.2.2 Global Epirubicin Hydrochloride API Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Epirubicin Hydrochloride API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Epirubicin Hydrochloride API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Epirubicin Hydrochloride API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Epirubicin Hydrochloride API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Epirubicin Hydrochloride API Revenue by Region
- 7.1 Global Epirubicin Hydrochloride API Revenue by Region
- 7.1.1 Global Epirubicin Hydrochloride API Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Epirubicin Hydrochloride API Revenue by Region (2021-2026)
- 7.1.3 Global Epirubicin Hydrochloride API Revenue by Region (2027-2032)
- 7.1.4 Global Epirubicin Hydrochloride API Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Epirubicin Hydrochloride API Revenue (2021-2032)
- 7.2.2 North America Epirubicin Hydrochloride API Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Epirubicin Hydrochloride API Revenue (2021-2032)
- 7.3.2 Europe Epirubicin Hydrochloride API Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Epirubicin Hydrochloride API Revenue (2021-2032)
- 7.4.2 Asia-Pacific Epirubicin Hydrochloride API Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Epirubicin Hydrochloride API Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Epirubicin Hydrochloride API Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Synbias-Gemini
- 8.1.1 Synbias-Gemini Company Information
- 8.1.2 Synbias-Gemini Business Overview
- 8.1.3 Synbias-Gemini Epirubicin Hydrochloride API Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Synbias-Gemini Epirubicin Hydrochloride API Product Portfolio
- 8.1.5 Synbias-Gemini Recent Developments
- 8.2 TAPI
- 8.2.1 TAPI Company Information
- 8.2.2 TAPI Business Overview
- 8.2.3 TAPI Epirubicin Hydrochloride API Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 TAPI Epirubicin Hydrochloride API Product Portfolio
- 8.2.5 TAPI Recent Developments
- 8.3 MicroBiopharm Japan
- 8.3.1 MicroBiopharm Japan Company Information
- 8.3.2 MicroBiopharm Japan Business Overview
- 8.3.3 MicroBiopharm Japan Epirubicin Hydrochloride API Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 MicroBiopharm Japan Epirubicin Hydrochloride API Product Portfolio
- 8.3.5 MicroBiopharm Japan Recent Developments
- 8.4 Olon S.p.A.
- 8.4.1 Olon S.p.A. Company Information
- 8.4.2 Olon S.p.A. Business Overview
- 8.4.3 Olon S.p.A. Epirubicin Hydrochloride API Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Olon S.p.A. Epirubicin Hydrochloride API Product Portfolio
- 8.4.5 Olon S.p.A. Recent Developments
- 8.5 Sterling Biotech
- 8.5.1 Sterling Biotech Company Information
- 8.5.2 Sterling Biotech Business Overview
- 8.5.3 Sterling Biotech Epirubicin Hydrochloride API Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Sterling Biotech Epirubicin Hydrochloride API Product Portfolio
- 8.5.5 Sterling Biotech Recent Developments
- 8.6 Lunan Pharmaceutical
- 8.6.1 Lunan Pharmaceutical Company Information
- 8.6.2 Lunan Pharmaceutical Business Overview
- 8.6.3 Lunan Pharmaceutical Epirubicin Hydrochloride API Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Lunan Pharmaceutical Epirubicin Hydrochloride API Product Portfolio
- 8.6.5 Lunan Pharmaceutical Recent Developments
- 8.7 Zhejiang Hisun
- 8.7.1 Zhejiang Hisun Company Information
- 8.7.2 Zhejiang Hisun Business Overview
- 8.7.3 Zhejiang Hisun Epirubicin Hydrochloride API Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Zhejiang Hisun Epirubicin Hydrochloride API Product Portfolio
- 8.7.5 Zhejiang Hisun Recent Developments
- 8.8 DZD (Heze) Pharmaceutical
- 8.8.1 DZD (Heze) Pharmaceutical Company Information
- 8.8.2 DZD (Heze) Pharmaceutical Business Overview
- 8.8.3 DZD (Heze) Pharmaceutical Epirubicin Hydrochloride API Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 DZD (Heze) Pharmaceutical Epirubicin Hydrochloride API Product Portfolio
- 8.8.5 DZD (Heze) Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Epirubicin Hydrochloride API Value Chain Analysis
- 9.1.1 Epirubicin Hydrochloride API Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Epirubicin Hydrochloride API Production Mode & Process
- 9.2 Epirubicin Hydrochloride API Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Epirubicin Hydrochloride API Distributors
- 9.2.3 Epirubicin Hydrochloride API Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst